Dupixent Injection, Solution
NDC Package 0024-5915-20
Package Information
Dupixent (dupilumab) injection is dUPIXENT is contraindicated in patients who have known hypersensitivity to dupilumab or any excipients of DUPIXENT [see Warnings and Precautions (5.1)]. This formulation utilizes a injection, solution delivery system. Marketed by Sanofi-aventis U.s. Llc, this product is identified by NDC 0024-5915 and is authorized under FDA application BLA761055.
Identification & Billing
- RxCUI: 1876401 - dupilumab 300 MG in 2 ML Prefilled Syringe
- RxCUI: 1876401 - 2 ML dupilumab 150 MG/ML Prefilled Syringe
- RxCUI: 1876401 - dupilumab 300 MG per 2 ML Prefilled Syringe
- RxCUI: 1876406 - DUPIXENT 300 MG in 2 ML Prefilled Syringe
- RxCUI: 1876406 - 2 ML dupilumab 150 MG/ML Prefilled Syringe [Dupixent]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0024 - Sanofi-aventis U.s. Llc
- 0024-5915 - Dupixent
- 0024-5915-20 - 2 SYRINGE, GLASS in 1 CARTON / 2 mL in 1 SYRINGE, GLASS (0024-5915-01)
- 0024-5915 - Dupixent
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0024-5915). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0024-5915-20 identifies a specific commercial package of 2 syringe, glass in 1 carton / 2 ml in 1 syringe, glass (0024-5915-01) of Dupixent, a human prescription drug labeled by Sanofi-aventis U.s. Llc. This injection, solution is formulated for subcutaneous use and contains dupilumab as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sanofi-aventis U.s. Llc on June 19, 2020. The current certification is valid through December 31, 2027.
How is this Sanofi-aventis U.s. Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00024591520. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 4 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.